{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:30Z","timestamp":1778940570362,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RO212301"],"award-info":[{"award-number":["RO212301"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493624047"],"award-info":[{"award-number":["493624047"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["511811315"],"award-info":[{"award-number":["511811315"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bneo.2025.100181","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T21:27:29Z","timestamp":1762464449000},"page":"100181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of European LeukemiaNet\u2013guided postremission therapy on outcomes of patients with AML from 2010 to 2022"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-2780","authenticated-orcid":false,"given":"Andrew F.","family":"Berdel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1955-0709","authenticated-orcid":false,"given":"Julian","family":"Ronnacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-9104","authenticated-orcid":false,"given":"Daniela V.","family":"Wenge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4850-7359","authenticated-orcid":false,"given":"Lina J.","family":"Kolloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4152-0366","authenticated-orcid":false,"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-9910","authenticated-orcid":false,"given":"Linus","family":"Angenendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-8097","authenticated-orcid":false,"given":"Tobias J.","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1899-3261","authenticated-orcid":false,"given":"Klaus","family":"Wethmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-5362","authenticated-orcid":false,"given":"Torsten","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf M.","family":"Mesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-6567","authenticated-orcid":false,"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.bneo.2025.100181_bib1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bneo.2025.100181_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bneo.2025.100181_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100181_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11899-019-00535-7","article-title":"Acute myeloid leukemia: from mutation profiling to treatment decisions","volume":"14","author":"DiNardo","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib8","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2008.352","article-title":"Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission","volume":"23","author":"Basara","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bneo.2025.100181_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.bneo.2025.100181_bib11","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100181_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100181_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2015.138180","article-title":"Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.bneo.2025.100181_bib15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","article-title":"Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial","volume":"35","author":"R\u00f6llig","year":"2021","journal-title":"Leukemia"},{"issue":"10388","key":"10.1016\/j.bneo.2025.100181_bib17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bneo.2025.100181_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100181_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.bneo.2025.100181_bib21","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100181_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: how to avoid a Babylonian confusion of languages","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","article-title":"European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol","volume":"6","author":"Bataller","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2025.100181_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cncr.31885","article-title":"Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes","volume":"125","author":"Boddu","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2025.100181_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100181_bib26","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","article-title":"Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years","volume":"34","author":"Eisfeld","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib27","doi-asserted-by":"crossref","first-page":"256.e1","DOI":"10.1016\/j.jtct.2020.12.021","article-title":"ELN 2017 genetic risk stratification predicts survival of acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Hansen","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bneo.2025.100181_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.01.008","article-title":"Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study","volume":"66","author":"Harada","year":"2018","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.bneo.2025.100181_bib29","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2025.100181_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2025.100181_bib32","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2025.100181_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-023-00835-5","article-title":"Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group","volume":"13","author":"Sargas","year":"2023","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib34","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bneo.2025.100181_bib35","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/leu.2016.25","article-title":"Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia","volume":"30","author":"Krug","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","article-title":"Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial","volume":"9","author":"Bornh\u00e4user","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100181_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized DaunoDouble trial by the study alliance leukemia","volume":"43","author":"Rollig","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100181_bib38","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100181_bib39","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1182\/blood-2022-163617","article-title":"Real-life comparative analysis of prognostic risk classification according to ELN 2010, 2017 and 2022 in AML patients","volume":"140","author":"Aparicio P\u00e9rez","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2020.11.001","article-title":"Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades","volume":"12","author":"Ihlow","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"10.1016\/j.bneo.2025.100181_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"10.1016\/j.bneo.2025.100181_bib43","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.bneo.2025.100181_bib44","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup","volume":"30","author":"B\u00fcchner","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish acute leukemia registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2025.100181_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102060","article-title":"Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000-2018","volume":"61","author":"Morton","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"6","key":"10.1016\/j.bneo.2025.100181_bib48","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/bjh.19436","article-title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard \u20187 + 3\u2019 induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study","volume":"204","author":"Rollig","year":"2024","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.bneo.2025.100181_bib49","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib50","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41409-019-0493-5","article-title":"Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival","volume":"54","author":"Chappell","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bneo.2025.100181_bib51","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100181_bib53","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2025.100181_bib54","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100181_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bneo.2025.100181_bib56","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100181_bib57","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","article-title":"Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study","volume":"98","author":"Ram","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100181_bib58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100181_bib59","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.bneo.2025.100181_bib60","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bneo.2025.100181_bib61","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bneo.2025.100181_bib62","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100181_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bneo.2025.100181_bib64","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bneo.2025.100181_bib65","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:23Z","timestamp":1778938643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2950328025001165"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100181","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of European LeukemiaNet\u2013guided postremission therapy on outcomes of patients with AML from 2010 to 2022","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100181"}}